Perioperative Chemotherapy for Potentially Resectable Gastric Cancer

Inclusion Criteria:

• Age 18 -75

• Histologically or cytologically proven in operable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction)

• ECOG performance status ≦2

• Tumor stage T3/4NxM0

• No distant metastasis (M0)

Exclusion Criteria:

• History of hypersensitivity to fluoropyrimidines, Tegafur，Gimeracil and OteracilPotassium Capsules , capecitabine, oxaliplatin or the ingredients of this product

• Inadequate hematopoietic function： WBC≦4,000/mm3; ANC≦2,000/mm3; Platelet≦100,000/mm3

• Inadequate organ function which is defined as below: Total bilirubin >2 pper limit of normal range (ULN); ALT / AST > 2.5 upper limit of normalrange (ULN) (>5.0 x ULN if hepatic metastasis); serum creatinine > 1.2 mg/dL, and Ccr > 60ml/min (estimated by Cockcroft-Gault formulation);

• Symptomatic peripheral neuropathy

• Receiving a concomitant treatment with other fluoropyrimidines

• Pregnancy or lactation women, or women with suspected pregnancy or men unless using areliable and appropriate contraceptive method.

• Mental status is not fit for chemotherapy therapy presence of serious concomitantillness which might be aggravated by study medication:

• Active cardiac disease e.g. decompensate myocardial infarction within the 6-monthperiod preceding entry into the study.

• History of ventricular arrhythmia or congestive heart failure.

• Significant co-morbid medical conditions, including, but not limited to, Chronicobstructive pulmonary disease, interstitial pneumonia ,pulmonary fibrosis, heartfailure, renal failure, hepatic failure, haemorrhagic peptic ulcer, mechanical orparalytic ileus, or poorly controlled diabetes.